Valuing early-stage biotech innovations can be challenging due to the inherent risks and uncertainties associated. Yet, strategic partnerships can enhance the asset’s valuation by providing access to resources, expertise, and potential market opportunities. How can partnerships be effectively structured to optimise value creation and provide a platform for long-term success? Are there partnership patterns and models which have proven to be effective? What are the contrasting strategies between platform-based innovations and single assets? How are future partners and investors evaluating collaborations in their due diligence?
Moderator: Claudia Andretta, Founder, Strategic Science & Business Advisor, Sichem Bio 
